Skip to main content
Premium Trial:

Request an Annual Quote

ArcherDx Closes $55M Series C Financing

NEW YORK – ArcherDx announced on Tuesday that it has closed a $55 million Series C financing round, led by Perceptive Advisors.

New investors Redmile Group, Soleus Capital, Driehaus Capital Management, and ArrowMark Partners joined the round, as well as existing investors Sands Capital, Longwood Fund, Boulder Ventures, and PBM Capital and affiliates, among others.

"The proceeds position ArcherDx to, upon approval, launch Stratafide to deliver the first multi-gene, pan-solid tumor companion diagnostic that accepts both tissue and blood, to benefit late-stage cancer patients," CEO and Cofounder Jason Myers said in a statement. "We will also advance our Personalized Cancer Monitoring platform, which is intended to leverage ArcherDx technology to improve detection of minimal residual disease and address critical needs in the early-stage solid tumor setting, including recurrence surveillance and therapy monitoring and evolution."

The firm will also use the proceeds to expand its global commercial footprint.

"We expect the company's flagship products to enable tailored therapeutic selection for cancer patients by providing actionable insights," Mike Altman, managing director of Perceptive Advisors, said in a statement. "Moreover, ArcherDx's [Anchored Multiplex PCR] technology enables decentralized testing, which we believe uniquely positions the company to broadly impact the molecular cancer testing market."

ArcherDx, based in Boulder, Colorado, has now raised more than $150 million. The firm closed a $60 million Series B round earlier this year and raised $35 million in a preferred Series A round that closed in March 2018.

Stratafide received a Breakthrough Device Designation from the US Food and Drug Administration in January.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.